查詢結果分析
來源資料
相關文獻
- Bisphosphonate Aggravates Secondary Hyperparathyroidism in Hemodialysis Patients
- Effect of Intravenous Calcitriol on Platelet Intracellular Calcium in Uremic Hemodialysis Patients with Secondary Hyperparathyroidism
- The Significance of Syphilis Serology Tests on Long-Term Hemodialysis Patients
- 小兒的腎臟移植
- Clinical Aspects of the Hemolytic Uremic Syndrome
- 尿毒症患者之結核病
- 尿毒症合併代謝性鹼血症之探討
- Effect of Arginine Vasopressin on Magnesium Handling in Rat Remnant Kidneys
- Characterization of Circulating Immunoreactive Parathyroid Hormone in Dialyzed and Nondialyzed Uremic Patients
- 尿毒症病患之異常出血傾向
頁籤選單縮合
題名 | Bisphosphonate Aggravates Secondary Hyperparathyroidism in Hemodialysis Patients=Bisphosphonate可加劇尿毒症患者次發性副甲狀腺功能之亢進 |
---|---|
作者 | 曾金鳳; 盧國城; 王進賢; 朱益民; 楊麗琼; | 書刊名 | 輔仁醫學期刊 |
卷期 | 2:4 民93.12 |
頁次 | 頁301-310 |
分類號 | 418.2183 |
關鍵詞 | 尿毒症; 鈣臨界點; 次發性副甲狀腺功能亢進; Bisphosphonate; Uremia; Calcium set point; Secondary hyperparathyroidism; |
語文 | 英文(English) |
中文摘要 | 背景及目的:Bisphosphonate 曾被報告能有效治療骨質疏鬆症。當患者使用此一藥物時,亦有引發低血鈣的可能性。然而,在副甲狀腺功能亢進合併骨質貧乏(Osteopenia) 的尿毒症患者,使用Bisphosphonate 是否會因低血鈣的發生,而加重次發性副甲狀腺功能亢進,目前仍未知曉。此一研究即在評估Bisphosphonate 對於合併次發性副甲狀腺功能亢進及骨質貧乏的尿毒症患者之血鈣及副甲狀腺功能之影響。方法:拾伍合併次發性副甲狀腺功能亢進(血清副甲狀腺濃度超過200 pg/ml) 及骨質貧乏(骨質密度T score < -1.0) 之尿毒症患者參與本研究。於血液透析最後壹小時,緩慢靜脈注射Bisphosphonate (Pamidronate 15mg)。給藥前及給藥後壹週,施行副甲狀腺功能動態試驗。本研究分別使用不同鈣離子濃度之血液透析液(分別為1meq/L 及4meq/L) 來進行血液透析,以誘導高血鈣及低血鈣的發生,藉以評估血漿鈣離子變化對副甲狀腺素分泌之動態功能狀況。結果:單一劑量Bisphosphonate 治療壹週後,可造成患者透析前基礎血漿鈣值顯著地從1.12 ± 0.03 下降到1.08 ± 0.05 mmol/L。而此一血鈣下降,不但使血中基礎副甲狀腺素值顯著地從362.3 ± 179.4 上升到630.1 ± 263.7 pg/ml;更可使副甲狀腺素-鈣曲線(PTH-Calcium curve) 之斜率(Slope) 顯著地增加(從-1872.6 ± 426.1 降到-2086.5 ± 571.1)。本研究也發現副甲狀腺素-鈣曲線中之副甲狀腺的鈣臨界點(calciumset point) 達到達統計學上之顯著增加情形。結論:短期使用Bisphosphonate 治療後,可使次發性副甲狀腺功能亢進之尿毒症患者,改變其經由血鈣的變動而調節副甲狀腺分泌之功能。Bisphosphonate 可經由血鈣的下降而加強刺激副甲狀腺素的分泌。同時,又可使副甲狀腺對血鈣的敏感度增加而更加劇次發性副甲狀腺功能亢進之嚴重度。 |
英文摘要 | Background and Purpose: Bisphosphonates have been reported to be effective in the treatment of patients with osteoporosis. Since patients on bisphosphonate may develop hypocalcemia, it is very likely that such therapy may aggravate secondary hyperparathyroidism in dialysis patients with osteopenia. This study investigated the short-term effects of bisphosphonate infusion on plasma calcium, serum parathyroid hormone (PTH) levels, and the calcium set point of the parathyroid gland in hemodialysis patients with secondary hyperparathyroidism. Methods: Fifteen patients with osteopenia on regular hemodialysis and with serum intact-PTH (PTH) levels of more than 200 pg/ml were included in this study. A second-generation bisphosphonate (pamidronate, Aredia(superscript ®) was administered intravenously as a single 15-mg dose in 150 ml of a 5% glucose solution for 1 h during the last hour of hemodialysis. The PTH responses to hypo- and hypercalcemia (induced with 1 and 4 meq/L of dialysate calcium, respectively) were evaluated before and 1 week after bisphosphonate administration. Results: Bisphosphonate infusion resulted in a reduction of predialysis plasma ionized calcium (iCa) of from 1.12±0.03 to 1.08±0.05 mmol/L (p<0.05), and an increase in the baseline PTH of from 362.3±179.4 to 630.1±263.7 pg/ml (p<0.001). The calcium set point for PTH showed an increasing trend after administration of bisphosphonate (1.12±0.03 vs. 1.15±0.04 mmol/L, p<0.05). The slope of the PTH calcium curve was slightly but significantly increased (-1872.6±426.1 vs. -2086.3±571.1, p<0.05) after bisphosphonate administration. Conclusion: Regulation of PTH secretion by calcium is altered after bisphosphonate administration in hemodialysis patients with secondary hyperparathyroidism. The reduction in plasma iCa not only induced a significant increase in PTH secretion but also increased the sensitivity of the parathyroid glands to calcium, which suggests that secondary hyperparathyroidism might worsen after administration of bisphosphonate. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。